Tazemetostat in Follicular Lymphoma: What Patients Need to Know After the Recent Market Withdrawal
On 9th March came the announcement that tazemetostat (Tazverik) is being voluntarily withdrawn worldwide. Ipsen, the company that markets tazemetostat, made this decision after new safety findings emerged from the ongoing SYMPHONY 1 clinical trial, which indicated a possible increased risk of secondary blood cancers when the drug was used in a specific combination regimen (lenalidomide and rituximab, also referred to as R2).
Epcoritamab Approved for Relapsed or Refractory Follicular Lymphoma on the NHS in England, Wales and Northern Ireland
NICE has approved epcoritamab (Tepkinly) on the NHS for adults in England, Wales and Northern Ireland with relapsed or refractory follicular lymphoma after two prior treatments. The decision introduces a new bispecific antibody therapy option for patients with limited treatment choices.
Celebrating the Women Researchers Driving Progress in Follicular Lymphoma Research
This International Women’s Day the FLF and our global community are proud to celebrate and highlight the exceptional women whose scientific insight, dedication and innovation are driving progress in follicular lymphoma research.
Follicular Lymphoma Conclave Brings Global Experts Together to Accelerate Progress Towards a Cure
In February 2026, the Follicular Lymphoma Foundation and the Josep Carreras Leukaemia Research Institute convened a global Scientific Conclave in Barcelona to confront the barriers slowing progress toward cures for follicular lymphoma. Over three days, leading experts aligned around clear priorities and a coordinated strategy designed to turn insight into decisive action for patients.
Latest Research Breakthroughs at ASH 2025: How We’re Accelerating the Search for a Cure
Every December, over 30,000 haematology experts from around the world gather for the American Society of Haematology (ASH) conference, where groundbreaking research is shared and the future of lymphoma treatment takes shape. In December 2025, the FLF team was at ASH in Orlando, USA on a clear mission: to find out the latest breakthroughs, represent you and drive progress toward a cure for follicular lymphoma.
2025 Impact Round-Up: Turning Belief into Progress for Follicular Lymphoma
In 2025 the FLF accelerated scientific momentum, strengthened global collaboration, and elevated the patient voice. In her first year as Global CEO, Emma France reflects on the turning points that pushed progress from possibility into action and shares how the FL community is shaping a future where cures become achievable.
Updates from the 2025 American Society of Hematology (ASH) Annual Meeting
The Follicular Lymphoma Foundation at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, one of the world’s premier gatherings for groundbreaking hematology research.
Epcoritamab-bysp in Combination with Rituximab and Lenalidomide Approved as Treatment Option for Relapsed or Refractory Follicular Lymphoma in the U.S.
On November 18, 2025, the FDA approved epcoritamab-bysp (EPKINLY®) in combination with rituximab and lenalidomide for adults with relapsed or refractory follicular lymphoma after at least one prior therapy. This approval applies to patients in the United States..
Unlock the Cure Gala 2025 Raises Funds for Vital Research
The Unlock the Cure Gala 2025 brought supporters together to fund vital research and deliver hope for people living with follicular lymphoma.
Highlights from our satellite symposium “Charting our Progress Towards a Cure”
At the recent 18th International Conference on Malignant Lymphoma (ICML), the FLF shone a spotlight on follicular lymphoma by hosting our very own satellite symposium for the second time, titled: “Charting our Progress Towards a Cure”. Read more to find out the key takeaways and highlights from the symposium.